- Conditions
- Alzheimer's Disease
- Interventions
- [F-18]W372
- Drug
- Lead sponsor
- Siemens Molecular Imaging
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Irvine, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 2,320
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fibromyalgia
- Interventions
- Traditional Acupuncture, Sham Treatment
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Alzheimer Disease, Chronic Traumatic Encephalopathy
- Interventions
- [F-18]Flornaptitril
- Drug
- Lead sponsor
- CereMark Pharma, LLC
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy, Multiparametric Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration
- Procedure · Radiation · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm, Somatostatin Positive Neoplastic Cells Present, Von Hippel-Lindau Syndrome
- Interventions
- Computed Tomography, Gallium Ga 68-Edotreotide, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- F-18 AV 1451
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Siltuximab
- Procedure · Biological
- Lead sponsor
- Timothy Voorhees
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Parkinson Disease, Healthy Volunteer
- Interventions
- [18F]NOS
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- 68Ga-PSMA-11, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Carcinoma
- Interventions
- Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
- Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alcohol Use Disorder
- Interventions
- [C-11], NOP-1A
- Radiation · Drug
- Lead sponsor
- Rajesh Narendran
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Healthy Subjects, Schizophrenia, Parkinson Disease
- Interventions
- Oxygen-15 Water
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,039 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1993
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Controls
- Interventions
- PET imaging
- Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Onvansertib, Gemcitabine, Nab-paclitaxel, Electrocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Computed Tomography
- Drug · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Thyroid Cancer
- Interventions
- Iodine-124, Positron Emission Tomography (PET)/Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Thyroid Cancer
- Interventions
- Cerenkov luminescence imaging.
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer
- Interventions
- 177Lu-PSMA-617
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Lipopolysaccharide
- Biological
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- ERα+ Breast Cancer, ESR1 Gene Mutation
- Interventions
- Tamoxifen, FES PET/CT
- Drug · Diagnostic Test
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin
- Conditions
- Cardiac Amyloidosis
- Interventions
- [18F]Fluselenamyl (FSA)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer Disease
- Interventions
- F 18 T807
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- PDAC - Pancreatic Ductal Adenocarcinoma, FAP
- Interventions
- [68Ga]FAPI-46
- Drug
- Lead sponsor
- SOFIE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • Rochester, Minnesota + 1 more
- Conditions
- Disorder of Consciousness, Traumatic Brain Injury
- Interventions
- Amantadine + L-DOPA, NMDA blocker
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York